0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Join our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free AccessPFS in (A) part I/run-in and (B) part II. A, Kaplan–Meier analysis of PFS with encorafenib plus binimetinib in naïve and pretreated patients in the FAS population. B, Kaplan–Meier analysis of PFS in the encorafenib plus binimetinib and ribociclib, encorafenib plus binimetinib and capmatinib, and encorafenib plus binimetinib and buparlisib arms.
Reinhard Dummer, Shahneen Sandhu, Wilson H. Miller, Marcus O. Butler, Matthew H. Taylor, Lucie Heinzerling, Christian U. Blank, Eva Muñoz‐Couselo, Howard A. Burris, Michael A. Postow, Bartosz Chmielowski, Mark R. Middleton, Carola Berking, Jessica C. Hassel, Anja Gesierich, Cornelia Mauch, Joseph F. Kleha, Anna Polli, Allison S. Harney, Alessandra di Pietro, Paolo A. Ascierto (2025). Figure 2 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma. , DOI: https://doi.org/10.1158/1078-0432.29221276.
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Preprint
Year
2025
Authors
21
Datasets
0
Total Files
0
Language
en
DOI
https://doi.org/10.1158/1078-0432.29221276
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free AccessYes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaboration
